초록접수[미리보기]
| 21KF-040 |
Analgesic effect of Panaphix in nociceptive pain models of Rats
1Department of Anesthesiology and
Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine,
Seoul, Republic of Korea
Background
Panaphix (PAX-1, sodium meta-arsenite or NaAsO2) is developed as a therapy for the treatment of various cancer and is known to have analgesic effects. The present study was aimed to investigate the analgesic effects of PAX-1 on nociception in rats.
Methods
The analgesic effect of PAX-1 on nociception was measured using the hot (52.5°C) and cold (2°C) plate test, and surgical incision. Six rats were divided into five groups, respectively; vehicle, 0.1, 1.0, and 10.0 mg/kg of PAX-1, and sham. PAX-1 was orally administered for a week before the hot and cold plate test, and a week after surgery for the treatment of surgical incisional nociception. The analgesic effect was evaluated by measuring the withdrawal threshold to a Von Frey filament in surgical incision group.
Results
Latency of the hot (vehicle vs. 0.1, 1.0, and 10 mg/kg of PAX-1; P=0.008, P=0.006, and P<0.001) and cold plate (vehicle vs. 1.0 and 10 mg/kg of PAX-1; P<0.001, and P<0.001) was significantly prolonged in PAX-1 groups than in vehicle. Compared to vehicle, the Von Frey values were significantly increased in PAX-1 groups when surgical incision test (postoperative day (POD) 1: vehicle vs. 10mg/kg of PAX-1, P=0.002; POD3: vehicle vs. 1.0 and 10 mg/kg of PAX-1, P<0.001 and P=0.008; POD7: vehicle vs. 0.1, 1.0 and 10 mg/kg of PAX-1, P<0.001 in all).
Conclusion
PAX-1 showed preventive and therapeutic effects for incision-evoked mechanical nociception and reduced heat and cold nociception in a rat model, suggesting PAX-1 may have analgesic effects for nociceptive pain.
Panaphix (PAX-1, sodium meta-arsenite or NaAsO2) is developed as a therapy for the treatment of various cancer and is known to have analgesic effects. The present study was aimed to investigate the analgesic effects of PAX-1 on nociception in rats.
Methods
The analgesic effect of PAX-1 on nociception was measured using the hot (52.5°C) and cold (2°C) plate test, and surgical incision. Six rats were divided into five groups, respectively; vehicle, 0.1, 1.0, and 10.0 mg/kg of PAX-1, and sham. PAX-1 was orally administered for a week before the hot and cold plate test, and a week after surgery for the treatment of surgical incisional nociception. The analgesic effect was evaluated by measuring the withdrawal threshold to a Von Frey filament in surgical incision group.
Results
Latency of the hot (vehicle vs. 0.1, 1.0, and 10 mg/kg of PAX-1; P=0.008, P=0.006, and P<0.001) and cold plate (vehicle vs. 1.0 and 10 mg/kg of PAX-1; P<0.001, and P<0.001) was significantly prolonged in PAX-1 groups than in vehicle. Compared to vehicle, the Von Frey values were significantly increased in PAX-1 groups when surgical incision test (postoperative day (POD) 1: vehicle vs. 10mg/kg of PAX-1, P=0.002; POD3: vehicle vs. 1.0 and 10 mg/kg of PAX-1, P<0.001 and P=0.008; POD7: vehicle vs. 0.1, 1.0 and 10 mg/kg of PAX-1, P<0.001 in all).
Conclusion
PAX-1 showed preventive and therapeutic effects for incision-evoked mechanical nociception and reduced heat and cold nociception in a rat model, suggesting PAX-1 may have analgesic effects for nociceptive pain.
|
|
